Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemiaBARNES, David J; SCHULTHEIS, Beate; ADEDEJI, Simisade et al.Oncogene (Basingstoke). 2005, Vol 24, Num 42, pp 6432-6440, issn 0950-9232, 9 p.Article

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)SCHERR, Michaela; CHATURVEDI, Anuhar; BATTMER, Karin et al.Blood. 2006, Vol 107, Num 8, pp 3279-3287, issn 0006-4971, 9 p.Article

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemiaBARNES, David J; PALAIOLOGOU, Danai; PANOUSOPOULOU, Eleni et al.Cancer research (Baltimore). 2005, Vol 65, Num 19, pp 8912-8919, issn 0008-5472, 8 p.Article

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaAPPERLEY, Jane F; GARDEMBAS, Martine; DIMITRIJEVIC, Sasa et al.The New England journal of medicine. 2002, Vol 347, Num 7, pp 481-487, issn 0028-4793Article

Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cellsKONIG, Heiko; HARTEL, Nicolai; SCHULTHEIS, Beate et al.Haematologica (Roma). 2007, Vol 92, Num 6, pp 838-841, issn 0390-6078, 4 p.Article

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34⁺ cellsVENTURINI, Letizia; BATTMER, Karin; CASTOLDI, Mirco et al.Blood. 2007, Vol 109, Num 10, pp 4399-4405, issn 0006-4971, 7 p.Article

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersJONES, Amy V; KREIL, Sebastian; WHITE, Helen et al.Blood. 2005, Vol 106, Num 6, pp 2162-2168, issn 0006-4971, 7 p.Article